Market open
Intra-Cellular Therapies/$ITCI
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Intra-Cellular Therapies
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. It maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Ticker
$ITCI
Sector
Trading on
Industry
Pharmaceuticals
Headquarters
Employees
860
ITCI Metrics
BasicAdvanced
$14B
-
-$0.72
0.72
-
Price and volume
Market cap
$14B
Beta
0.72
52-week high
$129.00
52-week low
$63.30
Average daily volume
3.5M
Financial strength
Current ratio
6.356
Quick ratio
5.7
Long term debt to equity
1.11
Total debt to equity
1.479
Management effectiveness
Return on assets (TTM)
-6.96%
Return on equity (TTM)
-8.58%
Valuation
Price to revenue (TTM)
19.458
Price to book
11.88
Price to tangible book (TTM)
11.88
Price to free cash flow (TTM)
-180.25
Growth
Revenue change (TTM)
46.62%
Earnings per share change (TTM)
-50.29%
3-year revenue growth (CAGR)
101.03%
3-year earnings per share growth (CAGR)
-40.84%
What the Analysts think about ITCI
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Intra-Cellular Therapies stock.
ITCI Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
ITCI Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
ITCI News
AllArticlesVideos
INTRA-CELLULAR THERAPIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Intra-Cellular Therapies, Inc. - ITCI
Business Wire·2 days ago
ITCI Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Intra-cellular Therapies, Inc. Is Fair to Shareholders
Business Wire·2 days ago
Intra-Cellular Therapies Reports Fourth Quarter and Full-Year 2024 Financial Results
GlobeNewsWire·6 days ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Intra-Cellular Therapies stock?
Intra-Cellular Therapies (ITCI) has a market cap of $14B as of February 27, 2025.
What is the P/E ratio for Intra-Cellular Therapies stock?
The price to earnings (P/E) ratio for Intra-Cellular Therapies (ITCI) stock is 0 as of February 27, 2025.
Does Intra-Cellular Therapies stock pay dividends?
No, Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders as of February 27, 2025.
When is the next Intra-Cellular Therapies dividend payment date?
Intra-Cellular Therapies (ITCI) stock does not pay dividends to its shareholders.
What is the beta indicator for Intra-Cellular Therapies?
Intra-Cellular Therapies (ITCI) has a beta rating of 0.72. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.